Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
SUPN Analyst Ratings
Moderate Buy
2 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SUPN Stock 12 Month Forecast
Average Price Target
$42.40
▲(2.84% Upside)
| Highest Price Target$46.00 | Average Price Target$42.40 | Lowest Price Target$36.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$46
Hold
11.57%
Upside
Downgraded
08/07/25
Supernus Pharmaceuticals' strong financial performance and strategic acquisitions are significant positives, supporting its growth trajectory. However, technical indicators suggest the stock is overbought, and valuation metrics indicate it may be overpriced. Additionally, patent challenges pose potential risks. Investors should weigh these factors carefully.
Stifel Nicolaus
$38→$43
Hold
4.29%
Upside
Reiterated
08/06/25
TD Cowen
$45
Buy
9.14%
Upside
Reiterated
08/05/25
We are encouraged by the recent weekly Rx data (as of July 25th), which indicates Qelbree is generating ~17,300 TRx/week, or a ~$285MM+ run-rate assuming $315/Rx. We are encouraged by the Rx momentum, ahead of the back-to-school season, and expect Qelbree to achieve $300MM (+24%) in 2025.We expect Qelbree will steadily grow as SUPN focuses on the adult launch, with increasing adoption in the segment. For perspective, adult ADHD Rx overall account for ~70% of the total market, and currently represents ~35% of Qelbree Rx (vs. 32% in 2024) – which mgmt expects could become 50/50 split. Our Qelbree clinician checks have been very positive on the real-world efficacy and tolerability.
Cantor Fitzgerald
$36→$42
Buy
1.87%
Upside
Upgraded
07/29/25
Piper Sandler
$36
Hold
-12.68%
Downside
Reiterated
06/17/25
Jefferies
$40
Buy
-2.98%
Downside
Reiterated
03/12/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$46
Hold
11.57%
Upside
Downgraded
08/07/25
Supernus Pharmaceuticals' strong financial performance and strategic acquisitions are significant positives, supporting its growth trajectory. However, technical indicators suggest the stock is overbought, and valuation metrics indicate it may be overpriced. Additionally, patent challenges pose potential risks. Investors should weigh these factors carefully.
Stifel Nicolaus
$38→$43
Hold
4.29%
Upside
Reiterated
08/06/25
TD Cowen
$45
Buy
9.14%
Upside
Reiterated
08/05/25
We are encouraged by the recent weekly Rx data (as of July 25th), which indicates Qelbree is generating ~17,300 TRx/week, or a ~$285MM+ run-rate assuming $315/Rx. We are encouraged by the Rx momentum, ahead of the back-to-school season, and expect Qelbree to achieve $300MM (+24%) in 2025.We expect Qelbree will steadily grow as SUPN focuses on the adult launch, with increasing adoption in the segment. For perspective, adult ADHD Rx overall account for ~70% of the total market, and currently represents ~35% of Qelbree Rx (vs. 32% in 2024) – which mgmt expects could become 50/50 split. Our Qelbree clinician checks have been very positive on the real-world efficacy and tolerability.
Cantor Fitzgerald
$36→$42
Buy
1.87%
Upside
Upgraded
07/29/25
Piper Sandler
$36
Hold
-12.68%
Downside
Reiterated
06/17/25
Jefferies
$40
Buy
-2.98%
Downside
Reiterated
03/12/25
Best Analysts Covering Supernus Pharmaceuticals
1 Month
xxx
Success Rate
9/13 ratings generated profit
Average Return
+0.45%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +0.45% per trade.
3 Months
xxx
Success Rate
9/13 ratings generated profit
Average Return
+6.28%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +6.28% per trade.
1 Year
2 Years
xxx
Success Rate
13/13 ratings generated profit
Average Return
+26.53%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +26.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SUPN Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
5
8
10
14
11
Hold
10
6
7
6
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
14
17
20
15
Each month's total comprises the sum of three months' worth of ratings.
SUPN Financial Forecast
SUPN Stock Forecast FAQ
What is SUPN’s average 12-month price target, according to analysts?
Based on analyst ratings, Supernus Pharmaceuticals’s 12-month average price target is 42.40.
What is SUPN’s upside potential, based on the analysts’ average price target?
Supernus Pharmaceuticals has 2.84% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SUPN a Buy, Sell or Hold?
Supernus Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.
What is Supernus Pharmaceuticals’s price target?
The average price target for Supernus Pharmaceuticals is 42.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $46.00 ,the lowest forecast is $36.00. The average price target represents 2.84% Increase from the current price of $41.23.
The highest analyst price target is $46.00 ,the lowest forecast is $36.00. The average price target represents 2.84% Increase from the current price of $41.23.
What do analysts say about Supernus Pharmaceuticals?
Supernus Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of SUPN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.